PL405115A1 - Aptamers having affinity to MDM2 protein, their compositions and the use thereof - Google Patents

Aptamers having affinity to MDM2 protein, their compositions and the use thereof

Info

Publication number
PL405115A1
PL405115A1 PL405115A PL40511513A PL405115A1 PL 405115 A1 PL405115 A1 PL 405115A1 PL 405115 A PL405115 A PL 405115A PL 40511513 A PL40511513 A PL 40511513A PL 405115 A1 PL405115 A1 PL 405115A1
Authority
PL
Poland
Prior art keywords
aptamers
affinity
mdm2 protein
compositions
mdm2
Prior art date
Application number
PL405115A
Other languages
Polish (pl)
Other versions
PL227370B1 (en
Inventor
Grzegorz Dubin
Aleksandra Pęcak
Stanisław Malicki
Paweł Majewski
Original Assignee
Uniwersytet Jagielloński
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Uniwersytet Jagielloński filed Critical Uniwersytet Jagielloński
Priority to PL405115A priority Critical patent/PL227370B1/en
Publication of PL405115A1 publication Critical patent/PL405115A1/en
Publication of PL227370B1 publication Critical patent/PL227370B1/en

Links

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Wynalazek dotyczy aptamerów stanowiących cząsteczki DNA posiadające powinowactwo do białka MDM2 oraz kompozycji zwierających aptamery. Wynalazek obejmuje także zastosowania aptamerów do wytwarzania leku do zwalczania chorób nowotworowych oraz do zastosowania do diagnostyki. Ujawniona w ramach wynalazku sekwencja nukleotydowa aptamerów oraz jej kompozycje wykazują właściwości specyficznego wiązania białka MDM2, które umożliwia antagonizowanie wiązania MDM2-p53 oraz zabijanie lub hamowanie wzrostu komórek nowotworowych.The invention relates to aptamers constituting DNA molecules having affinity for MDM2 protein and compositions containing aptamers. The invention also includes the use of aptamers for the manufacture of a medicament for combating cancer and for use in diagnostics. The aptamer nucleotide sequence disclosed in the context of the invention and its compositions exhibit MDM2 protein specific binding properties that allow antagonizing MDM2-p53 binding and killing or inhibiting tumor cell growth.

PL405115A 2013-08-22 2013-08-22 Aptamers having affinity to MDM2 protein, their compositions and the use thereof PL227370B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PL405115A PL227370B1 (en) 2013-08-22 2013-08-22 Aptamers having affinity to MDM2 protein, their compositions and the use thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PL405115A PL227370B1 (en) 2013-08-22 2013-08-22 Aptamers having affinity to MDM2 protein, their compositions and the use thereof

Publications (2)

Publication Number Publication Date
PL405115A1 true PL405115A1 (en) 2014-06-09
PL227370B1 PL227370B1 (en) 2017-11-30

Family

ID=50846671

Family Applications (1)

Application Number Title Priority Date Filing Date
PL405115A PL227370B1 (en) 2013-08-22 2013-08-22 Aptamers having affinity to MDM2 protein, their compositions and the use thereof

Country Status (1)

Country Link
PL (1) PL227370B1 (en)

Also Published As

Publication number Publication date
PL227370B1 (en) 2017-11-30

Similar Documents

Publication Publication Date Title
CY1123355T1 (en) ANTIBODIES TO CD73 AND USES THEREOF
PH12018500906A1 (en) Antibodies specifically binding pd-1 and their uses
CY1121517T1 (en) NON-FUCUCYLIZED ANTIBODIES ENANTI-FGFR2IIIB
CY1120035T1 (en) Pyrimidopyrimidinones usable as suspensions of WEE-1 kinase
CL2017001459A1 (en) Biaryl compounds useful for the treatment of human diseases in oncology, neurology and immunology
PH12016500330B1 (en) Certain chemical entities, compositions, and methods
EA201890754A1 (en) CONNECTIONS AND METHODS OF THEIR APPLICATION
UA117364C2 (en) Amatoxin derivatives
MX2016003843A (en) Irak inhibitors and uses thereof.
MX2021007663A (en) Target-tissue-specific antigen-binding molecule.
MX2015013163A (en) Multivalent and monovalent multispecific complexes and their uses.
EA201590997A1 (en) CONNECTIONS AND METHODS OF THEIR APPLICATION
MX2014009289A (en) C10rf32 antibodies, and uses thereof for treatment of cancer.
EA201590085A1 (en) ANTIBODIES ANTI-EGFR AND THEIR APPLICATION
NZ739622A (en) Antibodies to tau
TR201903009T4 (en) Exon skipping compositions for the treatment of muscular dystrophy.
PH12017500864A1 (en) Anti-notch1 antibodies
EA201490826A1 (en) ACC INHIBITORS AND THEIR APPLICATIONS
PH12015501059A1 (en) Anti-hemagglutinin antibodies and methods of use
MX2021010668A (en) Cytokine fusion proteins.
EA201492056A1 (en) Pyrimidinyl inhibitors of tyrosine kinase
WO2016065349A8 (en) Short non-coding protein regulatory rnas (sprrnas) and methods of use
MX2015011518A (en) Met-binding agents and uses thereof.
MX2022006304A (en) Compositions and methods for inhibiting the biological activity of soluble biomolecules.
MY165075A (en) Pharmaceutical composition comprising fimasartan and hydrochlorothiazide